 Anemia, Sickle Cell
"Anemia, Sickle Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Descriptor ID |
D000755
|
| MeSH Number(s) |
C15.378.071.141.150.150 C15.378.420.155 C16.320.070.150 C16.320.365.155
|
| Concept/Terms |
Anemia, Sickle Cell- Anemia, Sickle Cell
- Anemias, Sickle Cell
- Sickle Cell Anemias
- Hemoglobin S Disease
- Disease, Hemoglobin S
- Hemoglobin S Diseases
- Sickle Cell Anemia
- Sickle Cell Disorders
- Cell Disorder, Sickle
- Cell Disorders, Sickle
- Sickle Cell Disorder
- Sickling Disorder Due to Hemoglobin S
- HbS Disease
- Sickle Cell Disease
- Cell Disease, Sickle
- Cell Diseases, Sickle
- Sickle Cell Diseases
|
Below are MeSH descriptors whose meaning is more general than "Anemia, Sickle Cell".
- Diseases [C]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Anemia [C15.378.071]
- Anemia, Hemolytic [C15.378.071.141]
- Anemia, Hemolytic, Congenital [C15.378.071.141.150]
- Anemia, Sickle Cell [C15.378.071.141.150.150]
- Hemoglobinopathies [C15.378.420]
- Anemia, Sickle Cell [C15.378.420.155]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Anemia, Hemolytic, Congenital [C16.320.070]
- Anemia, Sickle Cell [C16.320.070.150]
- Hemoglobinopathies [C16.320.365]
- Anemia, Sickle Cell [C16.320.365.155]
Below are MeSH descriptors whose meaning is more specific than "Anemia, Sickle Cell".
This graph shows the total number of publications written about "Anemia, Sickle Cell" by people in this website by year, and whether "Anemia, Sickle Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 2 | 0 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 5 | 1 | 6 | | 2009 | 3 | 1 | 4 | | 2010 | 3 | 1 | 4 | | 2011 | 14 | 1 | 15 | | 2012 | 5 | 0 | 5 | | 2013 | 2 | 1 | 3 | | 2014 | 15 | 0 | 15 | | 2015 | 8 | 0 | 8 | | 2016 | 7 | 0 | 7 | | 2017 | 8 | 0 | 8 | | 2018 | 9 | 0 | 9 | | 2019 | 10 | 0 | 10 | | 2020 | 10 | 1 | 11 | | 2021 | 10 | 1 | 11 | | 2022 | 10 | 0 | 10 | | 2023 | 15 | 0 | 15 | | 2024 | 7 | 1 | 8 | | 2025 | 16 | 0 | 16 | | 2026 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Anemia, Sickle Cell" by people in Profiles.
-
Lucero MJ, Setua S, Thangaraju K, Khan A, Lamb DR, Lisk C, Swindle D, Cendali FI, Dzieciatkowska M, Stephenson D, Pak DI, Tolson R, Zaeske S, Rana NK, Khan S, Westover N, Davizon-Castillo P, George G, Hassell K, Nuss R, D'Alessandro A, Manolova V, Irwin DC, Buehler PW. Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice. Blood Adv. 2026 May 12; 10(9):3229-3242.
-
Strayer J, Wu X, Choe H, Iyer PR, Gómez-Pastora J, Moorman W, Cefaratti J, West A, Doon-Ralls J, Landes K, Della-Moretta S, Palmer AF, Zborowski M, Buehler PW, Chalmers JJ, Desai PC. Sickle cell vaso-occlusive episodes correlate with the magnetic heterogeneity of red blood cells. Blood Adv. 2026 Apr 28; 10(8):2836-2846.
-
Sridhar N, Song M, Stowell MHB, Hassell KL, Ding X. Acoustic probing of new biomarkers for rapid sickle cell disease screening. Lab Chip. 2026 Mar 31; 26(7):2187-2200.
-
Jenkins AM, Hendry E, Power-Hays A, Valentino M, Hall M, Kyler KE, Antoon JW, Tang Girdwood S, Goldman JL, Morel AN, Savage TJ, Orth LE, Archer NM. Increasing ketamine administration in children's hospitals for youth with sickle cell disease. Blood Adv. 2026 Feb 24; 10(4):1106-1113.
-
Jenkins AM, Hendry E, Power-Hays A, Valentino M, Hall M, Kyler KE, Antoon JW, Tang Girdwood S, Goldman JL, Morel AN, Savage TJ, Orth LE, Archer NM. Increasing ketamine administration in children's hospitals for youth with sickle cell disease. Blood Adv. 2026 Feb 24; 10(4):1106-1113.
-
Schlenz AM, Phillips SM, Mueller M, Humphrey D, Stevens J, Williams LP, Nickel RS, Dolatshahi L, Miller RE, Hulbert ML, Lee MT, Alvarez O, Fuh B, McNaull MA, Bhasin N, Melvin CL, Adams RJ, Kanter J. Successful implementation of stroke risk screening for sickle cell anemia in the DISPLACE study: results of a cluster randomized trial. Implement Sci. 2025 Nov 26; 20(1):50.
-
Gwarzo I, Coleman KD, McKinley K, Ellison AM, Alpern ER, Corboy J, Hariharan S, Topoz I, Wurtz M, Nielsen B, Cook LJ, Morris CR, Brandow AM, Campbell AD, Liem RI, Nuss R, Quinn CT, Thompson AA, Villella A, King AA, Baumann A, Frankenberger W, Brousseau DC. Opioid Timeliness in the Emergency Department and Hospitalizations for Acute Sickle Cell Pain. JAMA Pediatr. 2025 Nov 01; 179(11):1194-1202.
-
Miller CEF, Luehring JN, Kuna EBM, Bhatia S, Green AL, Compas BE. Shared Sociodemographic Risk Factors for Neurocognitive Dysfunction in Children With Cancer and Blood Disorders. Pediatr Blood Cancer. 2026 Jan; 73(1):e32131.
-
Edwards JG, Humphrey DT, Mueller M, Phillips S, Schlenz A, Oni MO, Kanter J, Bona K, Archer NM. Socioeconomic Status and Stroke Risk in Pediatric Sickle Cell Disease: A DISPLACE Study Secondary Analysis. Pediatr Blood Cancer. 2026 Jan; 73(1):e32112.
-
Phillips S, Martin K, Schlenz AM, Kanter J, Mueller M, Lebensburger J, Galandanci N, Fuh BR, Rivenbark C, Alvarez OA, Hanson RF, Madisetti M, Prentice M, Kelechi TJ. Self-Management for Youth Living with Sickle Cell Disease (SMYLS): A study protocol for a multisite randomized controlled trial testing a behavioral, mHealth app. Contemp Clin Trials. 2025 Nov; 158:108103.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|